In recent years, the trachoma market is anticipated to grow rapidly during the forecast period. Trachoma is an infectious eye illness caused by the bacteria Chlamydia trachomatis, and it is the largest cause of blindness and one of 20 neglected tropical diseases that impact one billion of the world's poorest people, according to the World Health Organization (WHO). Furthermore, according to the World Health Organization (2018), an estimated 89.1 million people have been treated with medicines to eliminate trachoma, boosting the market's revenue growth.
Frequently Asked Questions
The market is segmented based on Segmentation, By Treatment (Medication, Surgery, Others), Route of Administration (Oral, Topical, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2032
.
The Global Trachoma Market size was valued at USD 604.34 USD Million in 2024.
The Global Trachoma Market is projected to grow at a CAGR of 5.5% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
